课题基金 / 基金详情

Targeting ETS Factor ERG as a Novel Therapeutic for the Treatment of Prostate Cancer

Targeting ETS Factor ERG as a Novel Therapeutic for the Treatment of Prostate Cancer
靶向 ETS 因子 ERG 作为治疗前列腺癌的新疗法
批准号：
327813
负责人：
Roshan Moniri Mani
金额：
$7.65万
依托单位：
University of British Columbia
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2014
资助国家：
加拿大
项目状态：
已结题
起止时间：
2014-10-01 至 2017-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=327813&lang=en
关键词：
Cancer Biology & Therapeutics Molecular & Cellular Biology Of Cancer Prostate Cancer Therapeutic

项目摘要

项目成果

Roshan Moniri Mani的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Prostate cancer is one of the leading causes of cancer-related death in men worldwide. If diagnosed early, prostate cancer is curable by surgery and/or radiotherapy. In cases of locally advanced, recurrent, and metastatic disease, androgen deprivation th
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The effect of ERG inhibitors on the formation of tumor micro-environment and metastatic niche.
Targeting ETS Factor ERG as a Novel Therapeutic for the Treatment of Prostate Cancer
  • 批准号：
    315141
  • 项目类别：
  • 资助金额：
    $0.07万
  • 财政年份：
    2014
  • 负责人：
    Roshan Moniri Mani
  • 依托单位：
    University of British Columbia
Protective Effects of B7-H4 on Beta Cell Mass and Beta-Cell Secretory Function.
  • 批准号：
    201589
  • 项目类别：
    Studentship Programs
  • 资助金额：
    $1.27万
  • 财政年份：
    2010
  • 负责人：
    Roshan Moniri Mani
  • 依托单位：
    University of British Columbia